1
|
Vrablikova A, Brezani V, Psikal I, Fraiberk M, Sebela M, Fojtikova M, Kulich P, Hezova R, Masek J. Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein. Front Vet Sci 2023; 10:1116661. [PMID: 37056230 PMCID: PMC10086343 DOI: 10.3389/fvets.2023.1116661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 02/27/2023] [Indexed: 03/30/2023] Open
Abstract
Bovine papillomavirus type 1 L1 protein was produced in a baculovirus expression system and purified as virus-like particles (VLPs) by affinity chromatography using lectins. The morphological integrity of VLPs was confirmed by electron microscopy. Differences between the two detected variants were deciphered by mass spectrometry of peptides (MALDI-TOF). Mice were immunized with purified VLPs in doses of 10, 25, or 50 μg in combination with 1% saponin and 15% alhydrogel per dose as adjuvants. Analysis of the humoral immune response revealed increased levels of specific antibodies detected 3 weeks after the first immunization in all groups of animals. This was further significantly increased by the booster applied 3 weeks after the first dose, with the best immune response in a group of mice immunized by the largest dose of antigen. BPV1 L1 VLPs purified by affinity chromatography using lectins could be used for prophylactic immunization in veterinary medicine.
Collapse
Affiliation(s)
- Alena Vrablikova
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
- *Correspondence: Alena Vrablikova
| | - Veronika Brezani
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
| | - Ivan Psikal
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
- Dyntec spol s. r.o., Terezin, Czechia
| | - Martin Fraiberk
- Dyntec spol s. r.o., Terezin, Czechia
- Faculty of Science, Charles University, Prague, Czechia
| | - Marek Sebela
- Department of Biochemistry, Faculty of Science, Palacký University, Olomouc, Czechia
| | - Martina Fojtikova
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
| | - Pavel Kulich
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
| | - Renata Hezova
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
| | - Josef Masek
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
| |
Collapse
|
2
|
Srivastava V, Nand KN, Ahmad A, Kumar R. Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery. Vaccines (Basel) 2023; 11:vaccines11020479. [PMID: 36851356 PMCID: PMC9965603 DOI: 10.3390/vaccines11020479] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2023] [Revised: 02/06/2023] [Accepted: 02/14/2023] [Indexed: 02/22/2023] Open
Abstract
Virus-like particles (VLPs) are empty, nanoscale structures morphologically resembling viruses. Internal cavity, noninfectious, and particulate nature with a high density of repeating epitopes, make them an ideal platform for vaccine development and drug delivery. Commercial use of Gardasil-9 and Cervarix showed the usefulness of VLPs in vaccine formulation. Further, chimeric VLPs allow the raising of an immune response against different immunogens and thereby can help reduce the generation of medical or clinical waste. The economically viable production of VLPs significantly impacts their usage, application, and availability. To this end, several hosts have been used and tested. The present review will discuss VLPs produced using different yeasts as fermentation hosts. We also compile a list of studies highlighting the expression and purification of VLPs using a yeast-based platform. We also discuss the advantages of using yeast to generate VLPs over other available systems. Further, the issues or limitations of yeasts for producing VLPs are also summarized. The review also compiles a list of yeast-derived VLP-based vaccines that are presently in public use or in different phases of clinical trials.
Collapse
Affiliation(s)
- Vartika Srivastava
- Department of Clinical Microbiology and Infectious Diseases, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa
| | - Kripa N. Nand
- Department of Biological Sciences, Rensselaer Polytechnic Institute, Troy, NY 12180, USA
| | - Aijaz Ahmad
- Department of Clinical Microbiology and Infectious Diseases, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa
- Infection Control, Charlotte Maxeke Johannesburg Academic Hospital, National Health Laboratory Service, Johannesburg 2193, South Africa
| | - Ravinder Kumar
- Department of Biological Sciences, Rensselaer Polytechnic Institute, Troy, NY 12180, USA
- Correspondence:
| |
Collapse
|
3
|
Watanabe S, Shibahara T, Andoh K, Hatama S, Mase M. Production of immunogenic recombinant L1 protein of bovine papillomavirus type 9 causing teat papillomatosis. Arch Virol 2020; 165:1441-1444. [PMID: 32239294 DOI: 10.1007/s00705-020-04612-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Accepted: 03/06/2020] [Indexed: 11/25/2022]
Abstract
Bovine papillomavirus type 9 (BPV9) is a causative agent of severe teat papillomatosis. Considering the lack of efficient BPV culture methods, recombinant proteins such as virus-like particles developed through genetic engineering may serve as a useful tool for developing effective vaccines against BPV infection. In this study, we successfully produced immunogenic particles composed of recombinant L1 protein of BPV9 (rBPV9-L1), using a baculovirus expression system. rBPV9-L1-immunized mice produced BPV9-specific IgG, which did not cross-react with BPV type 6, which is another causative agent of teat papillomatosis. Hence, immunogenic rBPV9-L1 is potentially applicable as a vaccine candidate for teat papillomatosis.
Collapse
Affiliation(s)
- Satoko Watanabe
- National Institute of Animal Health, NARO, 3-1-5 Kannondai, Tsukuba, Ibaraki, 305-0856, Japan.
| | - Tomoyuki Shibahara
- National Institute of Animal Health, NARO, 3-1-5 Kannondai, Tsukuba, Ibaraki, 305-0856, Japan
- Department of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-58 Rinku-oraikita, Izumisano, Osaka, 598-8531, Japan
| | - Kiyohiko Andoh
- National Institute of Animal Health, NARO, 3-1-5 Kannondai, Tsukuba, Ibaraki, 305-0856, Japan
| | - Shinichi Hatama
- National Institute of Animal Health, NARO, 3-1-5 Kannondai, Tsukuba, Ibaraki, 305-0856, Japan
| | - Masaji Mase
- National Institute of Animal Health, NARO, 3-1-5 Kannondai, Tsukuba, Ibaraki, 305-0856, Japan
- United Graduate School of Veterinary Sciences, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1193, Japan
| |
Collapse
|
4
|
Production of highly immunogenic virus-like particles of bovine papillomavirus type 6 in silkworm pupae. Vaccine 2017; 35:5878-5882. [DOI: 10.1016/j.vaccine.2017.08.079] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Revised: 08/19/2017] [Accepted: 08/30/2017] [Indexed: 01/16/2023]
|
5
|
Módolo DG, Araldi RP, Mazzuchelli-de-Souza J, Pereira A, Pimenta DC, Zanphorlin LM, Beçak W, Menossi M, de Cassia Stocco R, de Carvalho RF. Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine. Vaccine 2017; 35:1590-1593. [PMID: 28222997 DOI: 10.1016/j.vaccine.2017.02.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2016] [Revised: 01/31/2017] [Accepted: 02/02/2017] [Indexed: 11/19/2022]
Abstract
Bovine papillomatosis is an infectious disease that is caused by bovine papillomavirus (BPV), which results in important economic losses. However, no BPV vaccines or effective treatment methods are commercially available to date. Moreover, the absence of papillomavirus replication in vitro makes the use of recombinant protein a promising candidate for vaccine formulations. Hence, we developed an integrated study on the L1 capsid protein of BPV-1, obtained from a bacterial expression system, regarding its purification, biosafety, thermostability and immunogenicity. The results indicated an absence of genotoxicity of the purified recombinant L1 protein, β-sheet prevalence of secondary structure folding, protein stability under high temperatures as well as the presence of capsomeres and VLPs. In addition, preliminary experimental vaccination of calves showed the production of specific antibodies against BPV-1 L1.
Collapse
Affiliation(s)
| | - Rodrigo Pinheiro Araldi
- Laboratório de Genética, Instituto Butantan, São Paulo, SP, Brazil; Programa de Pós-graduação Interunidades em Biotecnologia, Instituto de Ciências Biomédicas (ICB), Universidade de São Paulo (USP), São Paulo, SP, Brazil
| | - Jacqueline Mazzuchelli-de-Souza
- Laboratório de Genética, Instituto Butantan, São Paulo, SP, Brazil; Programa de Pós-graduação Interunidades em Biotecnologia, Instituto de Ciências Biomédicas (ICB), Universidade de São Paulo (USP), São Paulo, SP, Brazil
| | | | | | - Letícia Maria Zanphorlin
- Laboratório Nacional de Ciência e Tecnologia do Bioetanol, Centro Nacional de Pesquisa em Energia e Materiais, Campinas, SP, Brazil
| | - Willy Beçak
- Laboratório de Genética, Instituto Butantan, São Paulo, SP, Brazil
| | - Marcelo Menossi
- Instituto de Biologia, Departamento de Genética, Evolução e Bioagentes, Universidade Estadual de Campinas, Campinas, SP, Brazil
| | | | | |
Collapse
|